Access the full text.
Sign up today, get DeepDyve free for 14 days.
B. Kiesewetter, M. Mayerhoefer, J. Lukas, C. Zielinski, L. Müllauer, M. Raderer (2014)
Rituximab plus bendamustine is active in pretreated patients with extragastric marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma)Annals of Hematology, 93
A. Salar, E. Domingo-Domènech, C. Estany, M. Canales, F. Gallardo, O. Servitje, G. Fraile, C. Montalbán (2009)
Combination therapy with rituximab and intravenous or oral fludarabine in the first‐line, systemic treatment of patients with extranodal marginal zone B‐cell lymphoma of the mucosa‐associated lymphoid tissue typeCancer, 115
A Avilés, MJ Nambo, N Neri (2005)
Mucosa associated lymphoid tissue (MALT) lymphoma of the stomach: results of a controlled trialMed Oncol, 22
A. Ferreri, M. Ponzoni, M. Guidoboni, A. Resti, L. Politi, S. Cortelazzo, J. Demeter, F. Zallio, A. Palmas, G. Muti, G. Dognini, E. Pasini, A. Lettini, F. Sacchetti, C. Conciliis, C. Doglioni, R. Dolcetti (2006)
Bacteria-eradicating therapy with doxycycline in ocular adnexal MALT lymphoma: a multicenter prospective trial.Journal of the National Cancer Institute, 98 19
A. Avilés, M. Nambo, N. Neri, A. Talavera, S. Cleto (2005)
Mucosa-associated lymphoid tissue (MALT) lymphoma of the stomachMedical Oncology, 22
A. Ruskoné-Fourmestraux, W. Fischbach, B. Aleman, H. Boot, M. Du, F. Mégraud, C. Montalbán, M. Raderer, A. Savio, A. Wotherspoon (2011)
EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALTGut, 60
D. Aoki, S. Ueno, Fumitake Kubo, T. Oyama, T. Sakuta, K. Matsushita, I. Maruyama, T. Aikou (2005)
Roxithromycin inhibits angiogenesis of human hepatoma cells in vivo by suppressing VEGF production.Anticancer research, 25 1A
M. Raderer, S. Wöhrer, B. Streubel, J. Drach, U. Jäger, K. Turetschek, M. Troch, A. Püspök, C. Zielinski, A. Chott (2007)
Activity of Rituximab plus Cyclophosphamide, Doxorubicin/Mitoxantrone, Vincristine and Prednisone in Patients with Relapsed MALT LymphomaOncology, 70
A. Ferreri, M. Guidoboni, M. Ponzoni, C. Conciliis, S. Dell'oro, K. Fleischhauer, L. Caggiari, A. Lettini, E. Cin, R. Ieri, M. Freschi, E. Villa, M. Boiocchi, R. Dolcetti (2004)
Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas.Journal of the National Cancer Institute, 96 8
Introduction and overview of the classification of the lymphoid neoplasms
E. Zucca, A. Conconi, D. Laszlo, A. López-Guillermo, R. Bouabdallah, B. Coiffier, C. Sebban, F. Jardin, U. Vitolo, F. Morschhauser, S. Pileri, C. Copie-Bergman, E. Campo, A. Jack, I. Floriani, Peter Johnson, M. Martelli, F. Cavalli, G. Martinelli, C. Thieblemont (2013)
Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 5
P. Hammel, C. Haioun, Chaumette Mt, P. Gaulard, M. Diviné, F. Reyes, J. Delchier (1995)
Efficacy of single-agent chemotherapy in low-grade B-cell mucosa-associated lymphoid tissue lymphoma with prominent gastric expression.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 13 10
F. Suarez, O. Lortholary, O. Hermine, Marc Lecuit (2006)
Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation.Blood, 107 8
B. Kiesewetter, M. Troch, W. Dolak, L. Müllauer, J. Lukas, C. Zielinski, M. Raderer (2013)
A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma)Haematologica, 98
J. Vaillant, A. Ruskoné-Fourmestraux, P. Aegerter, B. Gayet, J. Rambaud, P. Valleur, R. Parc (2000)
Management and long-term results of surgery for localized gastric lymphomas.American journal of surgery, 179 3
G. Jäger, P. Neumeister, R. Brezinschek, T. Hinterleitner, W. Fiebiger, M. Penz, H. Neumann, B. Mlineritsch, M. Desantis, F. Quehenberger, A. Chott, C. Beham‐Schmid, G. Höfler, W. Linkesch, M. Raderer (2002)
Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: a phase II study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 18
T. Kim, Ki Kim, Min Lee, Y. Jeon, Se-Hoon Lee, Dong-Wan Kim, C. Kim, I. Kim, S. Khwarg, D. Heo (2010)
First‐line therapy with doxycycline in ocular adnexal mucosa‐associated lymphoid tissue lymphoma: A retrospective analysis of clinical predictorsCancer Science, 101
M. Raderer, B. Streubel, S. Woehrer, A. Puespoek, U. Jaeger, M. Formanek, A. Chott (2005)
High Relapse Rate in Patients with MALT Lymphoma Warrants Lifelong Follow-upClinical Cancer Research, 11
M. Lévy, C. Copie-Bergman, A. Amiot, J. Dupuis, Y. Baleur, K. Belhadj, F. Hemery, I. Sobhani, M. Delfau-Larue, K. Leroy, C. Haioun, J. Delchier (2013)
Rituximab and chlorambucil versus rituximab alone in gastric mucosa-associated lymphoid tissue lymphoma according to t(11;18) status: a monocentric non-randomized observational studyLeukemia & Lymphoma, 54
P. Isaacson, D. Wright (1983)
Malignant lymphoma of mucosa‐associated lymphoid tissue. A distinctive type of B‐cell lymphomaCancer, 52
B. Kiesewetter, M. Raderer (2013)
Antibiotic therapy in nongastrointestinal MALT lymphoma: a review of the literature.Blood, 122 8
S. Govi, G. Dognini, G. Licata, R. Crocchiolo, A. Resti, M. Ponzoni, A. Ferreri (2010)
Six‐month oral clarithromycin regimen is safe and active in extranodal marginal zone B‐cell lymphomas: final results of a single‐centre phase II trialBritish Journal of Haematology, 150
A. Salar, E. Domingo-Domènech, C. Panizo, C. Nicolás, J. Bargay, A. Muntañola, M. Canales, J. Bello, J. Sancho, J. Tomás, M. Rodríguez, F. Peñalver, L. Palomera, C. Grande, J. Sanchez-blanco, R. Arranz, E. Conde, D. Caballero, C. Montalbán (2012)
Final Results of a Multicenter Phase II Trial with Bendamustine and Rituximab As First Line Treatment for Patients with MALT Lymphoma (MALT-2008–01)Blood, 120
A. Ferreri, S. Govi, E. Pasini, S. Mappa, F. Bertoni, F. Zaja, C. Montalbán, C. Stelitano, M. Cabrera, A. Resti, L. Politi, C. Doglioni, F. Cavalli, E. Zucca, M. Ponzoni, R. Dolcetti (2012)
Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 24
R. Tsang, M. Gospodarowicz, M. Pintilie, W. Wells, D. Hodgson, A. Sun, M. Crump, B. Patterson (2003)
Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 21 22
M. Troch, B. Kiesewetter, W. Willenbacher, E. Willenbacher, A. Zebisch, W. Linkesch, M. Fridrik, L. Müllauer, R. Greil, M. Raderer (2013)
Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a phase II study by the Arbeitsgemeinschaft Medikamentöse TumortherapieHaematologica, 98
C. Thieblemont, F. Berger, C. Dumontet, I. Moullet, F. Bouafia, P. Felman, G. Salles, B. Coiffier (2000)
Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed.Blood, 95 3
S. Son, B. Choi, G. Kim, Suk-Woo Yang, Y. Hong, I. Choi, Yeon-Sil Kim (2010)
Primary radiation therapy in patients with localized orbital marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT Lymphoma).International journal of radiation oncology, biology, physics, 77 1
D. Aguiar-Bujanda, I. Llorca-Mártinez, J. Rivero-Vera, M. Blanco-Sánchez, Pedro Jiménez-Gallego, Marta Santiago, M. Limeres-González, José Cabrera‐Marrero, María Hernández-Sosa, Saray Galván-Ruíz, Samuel Hernández-Sarmiento, S. Grau, U. Bohn‐Sarmiento (2014)
Treatment of gastric marginal zone B‐cell lymphoma of the mucosa‐associated lymphoid tissue with rituximab, cyclophosphamide, vincristine and prednisoneHematological Oncology, 32
E. Chanudet, Yuanping Zhou, C. Bacon, A. Wotherspoon, H. Müller-Hermelink, P. Adam, H. Dong, D. Jong, Yun-quan Li, R. Wei, X. Gong, Q. Wu, R. Ranaldi, G. Goteri, S. Pileri, H. Ye, R. Hamoudi, Hongxiang Liu, J. Radford, Ming-Qing Du (2006)
Chlamydia psittaci is variably associated with ocular adnexal MALT lymphoma in different geographical regionsThe Journal of Pathology, 209
P. Isaacson, J. Spencer (1987)
Malignant lymphoma of mucosa‐associated lymphoid tissueHistopathology, 11
E. Zucca, C. Copie-Bergman, U. Ricardi, C. Thieblemont, M. Raderer, M. Ladetto (2010)
Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Annals of oncology : official journal of the European Society for Medical Oncology, 24 Suppl 6
While eradication of Helicobacter pylori leads to durable remissions in up to 75 % of patients with gastric mucosa-associated lymphoid tissue (MALT) lymphoma and therefore, has been well established as first-line therapy of choice, there is no standard of care for relapsed, refractory or extragastric MALT lymphoma. Both in gastric as well as extragastric MALT lymphoma, local therapy results in high rates of local control, but MALT lymphoma may be disseminated in a significant number of patients, making systemic treatment approaches reasonable. Different classical cytostatic agents have successfully been tested in the past. However, MALT lymphoma usually runs an indolent clinical course and thus, recent trials have focussed on chemotherapeutics with a favourable toxicity profile, e.g. chlorambucil or bendamustine with or without rituximab (R), and new immunomodulatory drugs, e.g. lenalidomide. Results are promising and further, and especially more mature data with a longer follow-up are awaited. In addition, efforts have been made to characterise the activity of antibiotic therapy in extragastric MALT lymphoma, particularly in the setting of ocular adnexal manifestations. Doxycyclin-treatment achieved response rates of 45–65 % in several series, which was independent of the presence of a Chlamydophila psittaci infection. Furthermore, the macrolide antibiotic clarithromycin has become a matter of interest for the treatment of ocular adnexal MALT lymphoma as this substance exerts not only antibiotic, but also direct anti-tumor and immunomodulatory effects. In view of recent data, this short review focuses on highlights and recent results of systemic and antimicrobial therapy in MALT lymphoma.
memo - Magazine of European Medical Oncology – Springer Journals
Published: Feb 25, 2014
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.